The Health Sciences Authority (HSA) has announced a correction to the Singapore prescribing information for Brukinsa Capsule 80 mg regarding dosage modifications when used with CYP3A inhibitors.

• Information corrected: Previous prescribing information for certain batches did not contain up-to-date dosage guidance for co-administration with CYP3A inhibitors.
• Professional guidance: Healthcare professionals are directed to use the updated information and disregard the outdated package inserts.
• Communication channel: The correction was issued via a Dear Healthcare Professional Letter.

This summary is based on a Dear Healthcare Professional Letter published by the Health Sciences Authority of Singapore.